Close Menu

NEW YORK – Austrian firm OncoLab Diagnostics is developing a range of liquid biopsy-based diagnostic products, starting with an assay for monitoring for late-stage cancer recurrence.

OncoLab expects to receive a CE mark later this year for its RT-qPCR test, which detects and characterizes epithelial CTCs that express cytokeratin-19 (CK-19) as a biomarker. In addition, the firm is leveraging a recently signed partnership with Axon Dx to improve assay development.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.